Introduction
Traditional medicines and, in particular traditional Chinese medicine, represent a valuable source of potential new antineoplastic drugs. The Encyclopaedia of Traditional Chinese Medicine (1977) (Zhong Yao Da Ci Dian) lists 45500 natural sources for the 100 000 ± 500 000 prescriptions of the Chinese Materia Medica (Zhu and Woerdenbag, 1995; Tang and Eisenbrand, 1992) . Of these, some are described as relieving cancer'. Several Chinese plants such as Camptotheca acuminata (camptothecin) and Cephalotaxus sp. (homoharringtonine/harringtonine) have provided compounds with signi®cant antitumour activity (Han, 1994) . Another example is the traditional medicinal recipe Danggui Longhui Wan (reviews in Ma and Yao, 1983; Han, 1994; Chang, 1985 ; references in Hoessel et al., 1999) , a mixture of 11 herbal medicines which has been customarily used to treat the symptoms of chronic myelocytic leukemia. In 1966, Chinese scientists embarked on the identi®cation of the active ingredient of this prescription (Chen and Xie, 1984; Wu et al., 1979) . The therapeutic action was traced down to one drug, Qing Dai (indigo naturalis), a dark blue powder prepared from the leaves of several indigo-producing plants. Although this powder contains a high level of the blue dye indigo, the antileukemia activity was attributed to indirubin, a red coloured isomer of indigo (see Hoessel et al., 1999 for references) (Figure 1 ). However, indirubin shows poor solubility, low absorption and presents gastrointestinal toxicity. Several indirubin analogues, such as N-methyl isoindigo, 5-chloro-indirubin and indirubin-3'-monoxime, have thus been synthesized for better pharmacological properties and reduced toxicity (Ji and Zhang, 1985; Wu et al., 1985; Li et al., 1996) . Although indirubins are used in clinical medicine, the mode of action of these chemotherapeutic agents has remained largely unclear until lately.
Recently we showed that indirubin-3'-monoxime inhibits, in a dose-dependent manner, the growth of various hematopoietic and non-hematopoietic cell lines by inducing an arrest in G1 and, in most cases, in G2/ M (Hoessel et al., 1999; Marko et al., 2001) . Indirubin and its analogues selectively inhibit cyclin-dependent kinases (CDKs) by competing with ATP for binding to the catalytic site of the kinase (Hoessel et al., 1999) . Indirubins are also potent ATP competitive inhibitors of glycogen synthase kinase-3 (Leclerc et al., 2001) . Because CDKs are essential in initiating and coordinating the cell division cycle phases, we hypothesized that the inhibition of cell proliferation induced by indirubins may be linked to their action on CDKs. In this study, we investigated whether indirubin-3'-monoxime alters CDK function while inhibiting cell proliferation. Two major conclusions can be drawn from this work. First, we present evidence that a G2 cell cycle block is induced through a process involving direct inhibition of the CDK1 catalytic activity. Second, we describe a second mechanism of action of indirubin-3'-monoxime: in nocodazole-synchronized cells, a transient treatment with indirubin-3'-monoxime leads to endoreplication followed by massive cell death. This eect may signi®cantly contribute to the antitumour properties of indirubins.
Results
Indirubin has been identi®ed as the active component of the Traditional Chinese Medicinal recipe Danggui Longhui Wan (Figure 1 ). In this study of the cell cycle eects of indirubins, we have used the more soluble, membrane permeable and cytoplasm accumulating analogue, indirubin-3'-monoxime . All experiments were carried out with the human breast epithelial cell line HBL-100, because it responds to indirubin-3'-monoxime by a striking arrest in G2/M (Hoessel et al., 1999) .
Indirubin-3'-monoxime reversibly arrests HBL-100 cells in G2/M Exponentially growing HBL-100 cells ( Figure 2a ) were exposed for 30 h to 15 mM indirubin-3'-monoxime and analysed by¯ow cytometry after PI staining. This treatment resulted in a striking accumulation of cells in G2/M (70.2%) (Figure 2b ) compared to control cells (10.4%), consistent with earlier results (Hoessel et al., 1999) . Epi¯uorescence microscopy of Hoechst 33342 stained cells showed morphologically normal nuclei at all cell cycle stages in control cells (Figure 2a) . In contrast, indirubin-3'-monoxime treated cells were characterized by large nuclei and the absence of metaphase ®gures (Figure 2b ). The average diameter/area of nuclei from control and treated cells was 15.4+3.7 mm/231+64 mm 2 and 19.8+2.3 mm/ 310+28 mm 2 , respectively. The G2 arrest was found to be completely reversible (Figure 3 ). When indirubin-3'-monoxime was washed away from treated cells by incubation in fresh complete medium, cells readily proceeded through M and entered the following G1 phase (Figure 3 ).
Indirubin-3'-monoxime does not alter the expression of major cell cycle regulators
We next investigated the mechanisms underlying the indirubin-3'-monoxime-induced G2 arrest. First we evaluated the eects of indirubin-3'-monoxime on the expression of cell cycle-relevant genes including various cyclins (A, B1, C, D2, D3, E), CDKs (1, 2, 4, 6), CDK inhibitors (p21 cip1 , p57 kip2 , p19
INK4D
) and key genes that aect the entry in, progression through and withdrawal from the cell cycle (E2F, egr-1, gadd45, mdm2, p53, Rb, c-myc, skp1, skp2, PCNA). b-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as internal standards. mRNAs were extracted and puri®ed from control and indirubin-3'-monoxime-treated HBL-100 cells. They were converted into single-stranded cDNA by PCR using a mixture of speci®c primers. 32 Plabelled cDNAs were then hybridized to the cDNAs immobilized on the`Cell cycle 1 GEArray' nylon membranes. The hybridization patterns were analysed with a PhosphorImager (Figure 4 ). This analysis revealed that indirubin-3'-monoxime does not alter the expression of the major cell cycle regulators. In agreement with the results obtained with this gene expression array system, cyclin A, B1 and CDK1 mRNA ( Figure 5a ) and protein levels ( Figure 5b ) were found to remain essentially unaltered following indirubin-3'-monoxime treatment. Only a slight increase in cyclin A, B1 and CDK1 protein levels was observed which may correlate with the accumulation of cells in G2 in the latest time points of the indirubin-3'-monoxime treatment. Altogether these results are consistent with the lack of eect of indirubin-3'-monoxime on expression of the major cell cycle regulators.
Indirubin-3'-monoxime arrests HBL-100 cells in G2/M by inhibiting CDK1/cyclin B An alternative explanation for the G2 arrest induced by indirubin-3'-monoxime could be a direct eect on the catalytic activity of CDK1/cyclin B. In vitro, this enzyme is indeed quite sensitive to indirubin-3'-monoxime (IC 50 : 0.18 mM) (Hoessel et al., 1999; Leclerc et al., 2001) . To investigate this hypothesis, we ®rst analysed the overall protein phosphorylation pattern using a polyclonal antibody which cross-reacts with phosphoThreonine followed by a Proline residue, as these sites are speci®cally phosphorylated by CDKs and Erks. Cells were exposed to indirubin-3'-monoxime, associated or not for the last 6 h incubation with colcemide. As controls, cells were left untreated or were exposed to nocodazole or colcemide. Extracts were prepared and total proteins were resolved by SDS ± PAGE and analysed with the anti-phospho-ThrPro antibodies (Figure 6a) . Colcemide (or nocodazole) treatment allows an accumulation of active CDK1/ cyclin B and this is re¯ected by a high level of the ThrPro phosphorylated proteins. In contrast indirubin-3'-monoxime treatment abolishes the colcemide-associated phosphorylations.
To further con®rm the direct inhibition of CDK1/ cyclin B, we analysed the proteins with TG3, an antibody which cross-reacts with nucleolin only when phosphorylated by CDK1/cyclin B (Vincent et al., 1996; Roberge et al., 1998) . Colcemide (or nocodazole) treatment leads to an accumulation of CDK1/cyclin Bphosphorylated nucleolin, a consequence of the accumulation of active CDK1/cyclin B in the M phase arrested cells (Figure 6b ). This eect is abolished by Figure 2 Indirubin-3'-monoxime arrests HBL-100 cells in G2/M. Asynchroneous, serum-stimulated HBL-100 cells were cultured in the absence (a, a') or presence (b, b') of 15 mM indirubin-3'-monoxime for 30 h. Following ®xation the cell cycle pro®les were analysed by¯ow cytometry (a, b) as described in the Materials and methods section. Samples of control and treated HBL-100 cells were also stained with Hoescht 33342 (a', b') indirubin-3'-monoxime ( Figure 6b ). Altogether these data suggest that indirubin-3'-monoxime inhibits the phosphorylation of proteins by CDK1/cyclin B.
We next investigated the CDK1/cyclin B kinase activity of indirubin-3'-monoxime-treated and control HBL-100 cells ( Figure 7 ). The complex was puri®ed from indirubin-3'-monoxime-treated and control cells by anity chromatography on p9
CKShs1
-sepharose beads (as described in Borgne and Meijer, 1996) and its kinase activity was assayed using histone H1 as a substrate. The kinase activity was signi®cantly higher in indirubin-3'-monoxime-treated cells relative to control cells. This surprising result can be explained as follows: ®rst, indirubin-3'-monoxime leads to the accumulation of cells in G2 (Figure 2 ), therefore with a high level of CDK1/cyclin B activity. Second, indirubin-3'-monoxime acts as a competitive and reversible inhibitor of ATP binding (Hoessel et al., 1999) , and it is likely that indirubin-3'-monoxime is removed from CDK1/cyclin B during the kinase puri®cation procedure which involves numerous washes of the anity chromatography matrix. However CDK1/cyclin B kinase activity is inhibited when indirubin-3'-monoxime is added in the kinase assay ( Figure 7) .
Altogether, this data is consistent with a mode of action of indirubin-3'-monoxime through reversible inhibition of the CDK1/cyclin B kinase activity.
Indirubin-3'-monoxime induces partial polyploidy in HBL-100 cells synchronized in M phase by nocodazole
In the previous part of this work we have treated cells which were mostly in G1 and S ( Figure 2a ). We next investigated the eects of indirubin-3'-monoxime on cells synchronized in M phase. The microtubuledestabilizing drug nocodazole (Hoebeke et al., 1976) (0.2 mg/ml for 24 h) was used as a synchronizing agent as it accumulates cells in M phase (prophase) in a reversible fashion (Figure 8a ,b,c). Analysis of cell cycle distribution showed that more than 90% of the cells were arrested in G2/M (Figure 8b ) and¯uorescence microscopy showed that about 60% were in prophase ( Figure 8b ). After removal of nocodazole and incubation in fresh medium, cell cycle progression was reinitiated and most cells moved into G1 ( Figure  8c ,c',e,e'). In contrast, addition of 15 mM indirubin-3'-monoxime for 12 h just after the release from nocodazole caused an apparent G2/M arrest ( Figure  8d ). When cells were released from this sequential treatment with nocodazole and indirubin-3'-monoxime and G2/M arrest two types of responses were observed ( Figure 8f ,f'). Cells either completed their division and returned to G1, or were able to re-initiate DNA synthesis without dividing, therefore increasing their DNA content from 4n to 8n (Figure 8f ,f'). Such an Figure 3 Indirubin-3'-monoxime-induced G2/M arrest is reversible. Exponentially growing HBL-100 cells were exposed to 15 mM indirubin-3'-monoxime for 30 h, then washed with PBS and incubated with fresh complete medium At the indicated times, cell samples were harvested and the distribution between the cell cycle phases was analysed by¯ow cytometry endoreplication was never observed when indirubin-3'-monoxime was transiently added to asynchroneous cells (data not shown).
Indirubin-3'-monoxime-induced polyploidy is followed by cell death
Cultures were next extended to allow at least 2 ± 3 cell cycles to occur after the nocodazole?transient indirubin-3'-monoxime treatment, in order to follow the fate of cells with abnormal DNA content. Nocodazoletreated, control cells, incubated in fresh medium for up to 84 h showed normal cell cycle pro®les ( Figure  9a,d,g ). In contrast those submitted to the sequential dual treatment showed aneuploidy/polyploidy and clear signs of cell death (Figure 9b ,e,h). However, when the indirubin-3'-monoxime treatment was continuous rather than transient, polyploidy appeared only Figure 4 Indirubin-3'-monoxime does not alter the expression of major cell cycle regulatory genes in HBL-100 cells. 32 P-labelled cDNA probes were prepared from 8 mg of total RNA isolated from HBL-100 cultured in the absence (a) or presence (b) of 15 mM indirubin-3'-monoxime for 30 h as described in the Materials and methods section. The probes were hybridized to gene-speci®c cDNA fragments spotted on`Human cell cycle-1 GEArray' membranes. Hybridization signals of the multiple cell cycle genes expressed in treated and control cells were quanti®ed with a phosphorimager. Positions:
Figure 5 Indirubin-3'-monoxime does not alter the expression and translation of CDK1, cyclin A and cyclin B in HBL-100 cells. The results obtained with the gene expression array were con®rmed by Southern blots (a) and Western blots (b) for CDK1, cyclin A and cyclin B. Using appropriate primers, speci®c 32 P-labelled cDNAs were prepared from 8 mg of total mRNA isolated at speci®c times from HBL-100 cultured in the absence or presence of 15 mM indirubin-3'-monoxime and analysed by Southern blotting as described in the Materials and methods section. GAPDH was used as a loading control. Proteins samples were also prepared and analysed by Western blotting for expression of CDK1, cyclin A and cyclin B later, and little cell death occurred (Figure 9c ,f,i). HBL-100 cells exposed to the dual nocodazole?indirubin-3'-monoxime treatment were analysed for cell death parameters using Annexin V and Propidium iodide ( Figure 10 ). Results clearly show that necrosis (31%) dominated over apoptosis (7%). Altogether these results indicate that following synchronization in prophase, indirubin-3'-monoxime interferes with HBL-100 cell cycle by allowing endoreplication which increases susceptibility to cell death.
Discussion
This work shows that indirubin-3'-monoxime has two major eects on HBL-100 cells. When asynchroneous cells are exposed to indirubin-3'-monoxime, they arrest in G2, and this arrest is fully reversible upon drug removal. However, when cells are ®rst synchronized in M phase, indirubin-3'-monoxime induces a polyploidy. Withdrawal of indirubin-3'-monoxime allows the polyploid cells to proceed through the next cell cycle, leading to aneuploidy, ultimately followed by cell death.
Indirubin-3'-monoxime induces a reversible G2 arrest
When added to exponentially growing, asynchronized HBL-100 cells, indirubin-3'-monoxime triggers a very sharp accumulation of cells in G2/M (Figure 2 ), con®rming earlier results (Hoessel et al., 1999; Marko et al., 2001 ). The nuclear and chromatin morphology (Figure 2b ) is indicative of a G2 arrest. We show here that this arrest is completely reversible: upon removal of indirubin-3'-monoxime, cells progress through the cell cycle (Figure 3 ). Furthermore this arrest is not accompanied by any signi®cant induction of cell death, nor by the expression of apoptosis-relevant genes (data not shown). These results are in agreement with the low toxicity described for indirubins in animal models and human testing (Institute of Haematology, 1981; Ji et al., 1981; Sichuan Institute of Traditional Chinese Medicine, 1981; Wang et al., 1981; Chang, 1985; Zhang et al., 1985) .
The mechanism underlying this G2 arrest was investigated in detail. A direct inhibition of CDK1/ cyclin B is supported by the following observations:
(1) indirubin-3'-monoxime does not trigger any signi®cant change in the expression of the major cell cycle regulators (Figures 4 and 5) , (2) indirubin-3'-monoxime inhibits the cellular phosphorylation of Thr-Pro sites, a consensus phosphorylation site for CDKs and ERKs (Figure 6a ), (3) indirubin-3'-monoxime inhibits the cellular phosphorylation of nucleolin at a CDK1/cyclin Bspeci®c site (Figure 6b ), (4) indirubin-3'-monoxime is a rather potent and selective inhibitor of CDK1/cyclin B in vitro (Hoessel et al., 1999, Figure 7 ). Although we were unable to observe a reduction of CDK1/cyclin B Figure 6 Indirubin-3'-monoxime inhibits the phosphorylation of Thr-Pro sites (a) and of nucleolin on M-phase speci®c sites (b). (a) Exponentially growing HBL-100 cells were exposed to 15 mM indirubin-3'-monoxime, associated or not with a ®nal 6 h incubation in 50 ng/ml colcemide, until a total 24 h period. As controls, cells were left untreated or were exposed to 0.2 mg/ml nocodazole or 50 ng/ml colcemide. Total proteins, resolved by SDS ± PAGE, were analysed with anti-phospho-Thr-Pro antibodies. (b) HBL-100 cells were treated as described above but analysed with TG3, an antibody which speci®cally cross-reacts with CDK1/cyclin B-phosphorylated nucleolin Figure 7 Indirubin-3'-monoxime inhibits CDK1/cyclin B. HBL-100 cells were cultured in the absence or presence of 15 mM indirubin-3'-monoxime for 24 and 30 h. Aliquots were harvested at these time points and frozen. CDK1/cyclin B, puri®ed by anity chromatography on p9
CKShsl -sepharose beads from 250 mg protein lysates, was assayed for its histone H1 kinase activity as described in the Materials and methods section. In addition 15 mM indirubin-3'-monoxime was also added in the in vitro kinase assays Oncogene Anti-mitotic properties of indirubins E Damiens et al activity in extracts (puri®ed on p9 CKShs -sepharose) of indirubin-3'-monoxime-treated HBL-100 cells (see Results), this was clearly seen in MCF-7 cells ). This discrepancy may be explained by the decrease in levels of total CDK1 and of cyclin B in complex with CDK1 which was detected in MCF-7 but not in HBL-100 cells. It may also arise from a dierent intracellular distribution of indirubin-3'-monoxime between the two cell lines. In MCF-7 cells indirubin-3'-monoxime distributes between the cytosol (44%) and particulate (56%) fractions ), (5) although indirubin-3'-monoxime is a powerful inhibitor of GSK-3 (Leclerc et al., 2001) , lithium, a reported GSK-3 inhibitor (Klein and Melton, 1996; Stambolic et al., 1996) , does not trigger a G2/ M arrest in HT-29 cells (data not shown). In HBL-100, lithium (0.5 ± 20 mM, 0.5 ± 30 mM) triggers an arrest in S phase (data not shown). The G2 arrest observed with indirubin-3'-monoxime is therefore unlikely to be due to an inhibition of GSK-3.
Indirubin-3'-monoxime induces polyploidy only in M phase-synchronized cells
When added to HBL-100 cells synchronized by a transient exposure to nocodazole, the majority of cells arrest in M phase (prophase) (M sub-population), while a fraction is still in G2 (G2 sub-population). When indirubin-3'-monoxime is added to this mixed population it triggers an apparent arrest of cells in G2/ M ( Figure 8d ). The nuclear and decondensed chromatin morphology (Figure 8d' ), the FACS analysis (Figure 8d) , and the consequences of drug removal (see below) ( Figure 8f ,f') show that this arrest corresponds to a mixture of polyploid G1 stage cells (derived from the M sub-population) and of G2 arrested cells (derived from the G2 sub-population). However, as indirubin-3'-monoxime is removed from the culture media, some cells (derived from the G2 subpopulation) re-enter a normal cell cycle (G1/S) while others (derived from the M sub-population) undergo re-replication (leading to 8n) (Figure 8f ). This poly- ploidy is never observed when either asynchroneous or serum starvation-synchronized HBL-100 cells are transiently exposed to indirubin-3'-monoxime. Polyploidy is only observed when cells are synchronized by nocodazole prior to exposure to indirubin-3'-monoxime. Polyploidy is much more rapidly induced when the indirubin-3'-monoxime treatment is transient rather than continuous (Figure 9 ). Polyploidy associated with a G2/M arrest and CDK1 inhibition triggered by various treatments has been observed in other instances. For example sodium butyrate indirectly inhibits, through enhanced expression of p21 cip1 , cyclin A and B associated CDKs and leads to G2 arrest followed by DNA re-replication (Yamada and Kimura, 1985; Lallemand et al., 1999) . Treatment of cells with the protein kinase inhibitors K-252A (Usui et al., 1991) or 6-dimethylaminopurine (Romanowski and Madine, 1996) inhibits mitosis but induces endoreplication. Both compounds inhibit CDKs but also many other protein kinases (data not shown; Meijer and Pondaven, 1988) . Treatment of nocodazole-synchronized A431 cells (Akiyama et al., 1999) or SBC3 cells (Ikegami et al., 1996) by CGP41251 leads to polyploidy and it has been suggested that this may contribute to the antitumour properties of this staurosporine derivative. A brief treatment of M phase-arrested cells with staurosporine results in the induction of a G1 reset followed by Figure 9 Indirubin-3'-monoxime-triggered polyploidy is followed by cell death. (Experimental protocol is summarized in the upper scheme). Exponentially growing HBL-100 cells were cultured in the presence of 0.2 mg nocodazole/ml for 24 h. Cells were then washed with PBS and (i) cultured in fresh complete medium (a, d, g), (ii) cultured with 15 mM indirubin-3'-monoxime for 12 h (b, e, h) and then incubated in fresh medium for another 24, 48 or 70 h, respectively, or (iii) cultured continuously with 15 mM indirubin-3'-monoxime (c, f, i). Cells were analysed for cell cycle distribution by¯ow cytometry polyploidy (Hall et al., 1996) . The forced expression of p21 cip1 also leads to endoreplication (Bates et al., 1998; Niculescu et al., 1998) . A cell line (HT2-19) has been generated in which endogenous CDK1 expression depends on the presence of an inducer in the culture medium (Itzhaki et al., 1997) . In the absence of inducer, these cells undergo extensive DNA re-replication and cell death.
Inhibition of GSK-3 by indirubin-3'-monoxime is unlikely to explain the induced polyploidy, as lithium (0.5 ± 20 mM; 0.5 ± 30 mM) does not trigger polyploidy in nocodazole-synchronized HBL-100 cells (data not shown).
The origin of this G2 arrest-associated polyploidy clearly deserves further investigation. Instead of completing mitosis, cells exposed to the nocodazole?indirubin-3'-monoxime treatment seem to undergo a DNA re-replication, or endoreplication. We saw no morphological evidence for a direct inhibition of cytokinesis (i.e. the presence of binucleated cells), which could have explained the polyploidy. Alternatively, an inhibition of cytokinesis followed by subsequent nuclear fusion of the binucleated cells, as described by Brodsky and Uryvaeva (1977) could account for the polyploidy induced by indirubin-3'-monoxime. We favor the following hypothesis: selective inhibition of CDK1/cyclin B may trigger some sort of accelerated exit from mitosis, without cell division, followed by DNA replication, consequently leading to an abnormal increase in the cellular DNA content.
Indirubin-3'-monoxime-induced polyploidy is followed by cell death
Following polyploidy induced by a transient indirubin-3'-monoxime treatment of nocodazole-synchronized HBL-100 cells, massive cell death occurs ( Figures  9e,h and 10) . This is only observed with the dual transient nocodazole?transient indirubin-3'-monoxime treatment. FACS analysis with Annexin V/propidium iodide staining shows that necrosis mostly contributes to the observed cell death. We believe that polyploidy is followed by aneuploidy, and this abnormal DNA content renders cell fragile during subsequent cell cycles. Interestingly, when the indirubin-3'-monoxime treatment, after nocodazole synchronization, is continuous rather than transient, HBL-100 cells undergo very little cell death. We feel that this can be explained as follows: in the continuous presence of inhibitor, cells remain arrested in G2 (8n), therefore do not divide, little aneuploidy develops and, as a consequence, cell death does not occur.
Numerous CDK inhibitors trigger cell death, mostly when associated with other treatments (Ongkeko et al., 1995; Bible and Kaufmann, 1997; Atienza et al., 2000; Edamatsu et al., 2000; review in Meijer and Kim, 1997; Borgne and Meijer, 1999; Meijer, 2000) . However this death can be accounted for mostly by apoptosis rather than by necrosis. Cell death induced by indirubin-3'-monoxime under the conditions described here is clearly dierent: (1) it requires synchronization of cells in prophase; (2) it requires a transient treatment with the inhibitor, most probably to allow several cell cycles to occur; (3) it is a consequence of aneuploidy, which itself derives from polyploidy; (4) it requires a few cell cycles to develop; (5) it consists mostly of necrosis. We are now carrying out experiments to investigate the generality of this mechanism. Is it found in all cell lines following the nocodazole?transient indirubin-3'-monoxime treatment? Is it observed whatever the method of synchronization in prophase? Is it observed with all CDK inhibitors? If induction of cell death by the speci®c treatment of M phase synchronized cells by CDK inhibitors were to be general, we might have a grasp on a method to control and improve the antitumor activity of CDK inhibitors. Figure 10 Indirubin-3'-monoxime-triggered cell death displays mostly characteristics of necrosis. HBL-100 undergoing cell death following nocodazole synchronization followed by a transient exposure to 15 mM indirubin-3'-monoxime were analysed by¯ow cytometry analysis using annexin-V-FITC and propidium iodide. N, necrosis; A, apoptosis
Materials and methods
Cell culture and treatments SV-40 transformed human breast epithelial cells HBL-100 were cultured in Dulbecco's modi®ed Eagle's medium (Gibco-BRL) supplemented with 10% FCS, 2 mM Lglutamine and gentamycine (Gibco-BRL) at 378C in a humidi®ed atmosphere containing 5% CO 2 in air.
Exponentially growing cells were incubated for 30 h with 15 mM indirubin-3'-monoxime (stock solution dissolved in DMSO). Nocodazole treatment of the cells was performed at a concentration of 0.2 mg/ml of medium for 24 h. Following the nocodazole treatment, cells were washed twice with phosphate-buered saline (PBS) and cultured in fresh medium with or without indirubin-3'-monoxime for 12 h. Cells were then washed with medium and placed in fresh complete medium for the indicated times before collection.
Fluorescence microscopy and flow cytometry cell cycle analysis
Cells were grown on slide at 80% con¯uence and treated as described above. At the indicated times after the various treatments, adherent cells were washed with PBS and ®xed for 30 min in 1% paraformaldehyde in PBS. After ®xation, cells were rinsed with deionized water and dried thoroughly. Cells were then stained for 5 min with 0.5 m/ml Hoechst 33342 (Sigma) in PBS and rinsed rapidly with PBS. Hoechststained cells were observed (206objective, calibrated with a micrometer) under UV with an epi¯uorescence microscope (Olympus) equipped with a CCD camera Eurocams Spot (Diagnostic Instruments, Inc.). Nuclei sizes and areas were estimated using the Spot RT software 3.0 (Diagnostic Instruments, Inc.).
In parallel, adherent cells were trypsinized, collected by centrifugation and ®xed in cold 70% ethanol for 4 h. Fixed cells were washed with PBS, incubated with 10 mg/ml of RNAse A (Sigma) and stained with 25 mg/ml of propidium iodide (Sigma) for 1 h at 378C. The stained cells were then analysed for cell cycle distribution on a FACSort¯ow cytometer (Becton Dickinson). Cell cycle analyses were done using multiCYCLE (P Rabinovitch). This program models DNA histograms following the algorithm of Dean and Jett as the sum of two gaussian peaks for G1 and G2 cells and of a polynomial function broadened by gaussian variability for S cells. Initially, the fractions of cells in G1 (position of G1 peak, variation coecient of G1 peak) are estimated interactively and then ®tted nonlinearly using the Marquardt algorithm. Evaluation of cell death was performed with the Annexin-V-FLUOS staining kit as speci®ed by the manufacturer (Boehringer Mannheim). Brie¯y, 3.10 5 cells were collected by centrifugation and resuspended in 500 ml staining solution+medium (V/V) containing 3 ml Annexin-V-FLUOS and 7 mg/ml propidium iodide. Cells were then incubated in the dark at room temperature for 15 min and analysed bȳ ow cytometry.
Gene expression analysis
Total RNA was isolated by the SNAP kit as speci®ed by the manufacturer (InVitrogen). Eight microgram total RNA samples were converted into 32 P-labelled ®rst-strand cDNAs using a mixture of primers speci®c for analysing cell cycle gene expression. cDNA probes were puri®ed on Chroma Spin-200 DEPC-H20 columns (Clontech) and hybridized to cDNAs spotted on positively charged nylon membranes as described by the human Cell-cycle 1 GEArray user manual (SuperArray Inc.). After high stringency washes, the hybridization patterns were quanti®ed with a PhosphorImager (Molecular Dynamics).
Results of GEArray experiments were con®rmed by RT ± PCR. Five micrograms of total RNA were converted into ®rst strand cDNAs. The ®rst strand cDNA synthesis reaction was primed using random hexamers and catalyzed by SuperScript II reverse transcriptase according to the manufacturer's instructions of the SuperScript Preampli®ca-tion System (Life Technologies, Inc.). Then, the ®rst strand cDNAs obtained was directly ampli®ed by PCR. The PCR reaction was carried out under the conditions recommended by the manufacturer (Life Technologies, Inc.). Brie¯y, 50 ml of the reaction mixture containing 2 ml (10%) of ®rst strand cDNA and 10 pmol of each primer was subjected to 25 cycles (denaturation at 948C for 3 min, annealing at 558C (cyclin A), 538C (cyclin B1) and 508C (Cdk1) for 2 min and polymerization at 728C for 3 min). The following set of primers and oligonucleotides were used for PCR ampli®ca-tion and for the detection of PCR products, respectively: cyclin B1 (forward: 5'-AATGCTGAAAATAAGGCG-3', reverse: 5'-CATCTTCTTGGGCACACA-3', probe: 5'-CGCCTGAGCCTATTTTGGTT-3'), cyclin A (forward: 5'-CTGCTGCTATGCTGTTA-3', reverse: 5'-GGTAGGTC-TGGTGAAGGT-3', probe: 5'-CCCCCAGAAGTAGCA-GAGTT-3'), Cdk1 (forward: 5'-TTCAGGATGTGCTTA-TGC-3', reverse: 5'-AGAGCAATTCCAAGCCAT-3', probe: 5'-TTCTATCCCTCCTGGTCAGT-3'). Ampli®ed products were subjected to electrophoresis on 1% agarose gel followed by ethidium bromide staining for detection using UV transillumination. PCR products were blotted onto Hybond N+ membranes (Amersham) by the method of Southern. Membranes were then hybridized overnight at 508C with the oligonucleotide probes which were 32 P-labelled using the Ready-To-Go DNA Labelling Beads kit as speci®ed by the manufacturer (Amersham). After high stringency washes (26SSC, 1% SDS; 0.16SSC, 0.5% SDS at 558C) membranes were autoradiographed at 7808C. The cDNA of GAPDH was also ampli®ed and signals obtained with the cyclin A, cyclin B1 and CDK1 probes were normalized to GAPDH signals obtained on the same blot to control for variations in loading and transfer among samples.
Immunoblotting analysis
Protein extraction was performed by lysing cells for 2 h at 48C in a buer containing (155 mM NaCl, 10 mM Tris pH 7.4, 1% Triton X-100, 1% deoxycholic acid, 1 mM EGTA, and phosphatase and protease inhibitors (10 mM NaF, 200 mM sodium orthovanadate, 200 mM aprotinin, 50 mg/ml leupeptin, 1 mM phenylmethyl sulphonyl¯uoride, 1 mM benzamidine and 10 mg/ml soybean trypsin inhibitor). Cellular debris were removed from soluble extracts by centrifugation at 10 000 g for 15 min at 48C and supernatants were frozen until analysis. Equal amounts of protein (100 mg), determined by the Bradford method, were loaded and run on 10% SDS-polyacrylamide gels, followed by a transfer onto nitrocellulose membranes (Schleicher & Schuell) . Blots were blocked in TBS (Tris-HCl pH 7.4, 150 mM NaCl) plus 5% dried milk for 1 h at room temperature and then probed with primary antibody diluted in Tris-buered saline (TBS) for 1 h at room temperature. Antibodies and dilutions were as follows: cyclin A (Santa Cruz Sc-751), 1 : 00 dilution; cyclin B1 (Dako M3530), 1 : 000 dilution; Cdk1 (Transduction Laboratories C12720), 1 : 500 dilution; TG3 antibodies (a kind gift from P Davies, New York), 1 : 000 dilution; anti-phospho Threonine-Proline antibodies (New England Biolabs), 1 : 000 dilution. Membranes were then washed with TBS four times for 15 min, incubated with peroxidase-linked secondary antibody (1 : 000, dilution) in TBS for 1 h at room temperature and washed four times for 15 min in TBS. Blots were then developed with the ECL system (Amersham).
Histone H1 kinase activity
Two hundred and ®fty-microgram samples of total lysates were mixed for 30 min at 48C with 20 ml of p9
CKShs1
-sepharose beads plus homogenization buer pH 7.2 (60 mM b-glycerophosphate, 15 mM nitrophenylphosphate, 25 mM MOPS, 15 mM EGTA, 15 mM MgCl 2 , 2 mM DTT, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml soybean trypsin inhibitor, 100 mM benzamidine) in a ®nal volume of 800 ml. The beads were then washed four times in 1 ml bead buer pH 7.4 (50 mM Tris A, 5 mM NaF, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% NP-40, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml soybean trypsin inhibitor, 100 mM benzamidine) and twice in 200 ml buer C pH 7.0 (60 M b-glycerophosphate, 30 mM nitrophenylphosphate, 25 mM MOPS, 5 mM EGTA, 15 mM mgCl 2 , 1 mM DTT, 0.1 mM Na 3 VO 4 , 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml soybean trypsin inhibitor, 100 mM benzamidine). Histone H1 kinase activity was assayed with 1 mg/ml histone H1 (Sigma, type III-S), in the presence of 15 mM [g-p 32 ]-ATP (3000 Ci/mMole; 1 mCi/ml) in a ®nal volume of 15 ml. Reactions were carried out for 30 min at 308C and stopped by incubation in ice. Twenty-®ve ml aliquots of supernatant were spotted onto 2.563 cm pieces of Whatman P81 phosphocellulose paper. The ®lters were then washed ®ve times for 5 min in 1% phosphoric acid and counted in the presence of 1 ml ACS scintillation¯uid (Amersham).
Abbreviations CDK, cyclin-dependent kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PBS, phosphate-buered saline; TBS, Tris-buered saline
